Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
Praxis Precision Medicines (NASDAQ: PRAX) has announced its participation in the Movement Disorders Society (MDS) 2024 International Congress in Philadelphia, Pennsylvania, from September 27 to October 1, 2024. The company will present a poster and platform talk showcasing its Phase 3 clinical program for ulixacaltamide, a potential therapy for adults with essential tremor (ET).
The presentations will focus on the Essential3 program, an innovative multi-study Phase 3 initiative evaluating the efficacy and safety of ulixacaltamide. Praxis will be available at booth #1008 and will deliver a platform presentation on September 28 and a poster presentation on September 29. Presentation materials will be made available on the company's website following the conference.
Praxis Precision Medicines (NASDAQ: PRAX) ha annunciato la sua partecipazione al Congresso Internazionale della Society for Movement Disorders (MDS) 2024 a Filadelfia, Pennsylvania, dal 27 settembre al 1 ottobre 2024. L'azienda presenterà un poster e una presentazione piattaforma che metterà in evidenza il suo programma clinico di Fase 3 per ulixacaltamide, una potenziale terapia per adulti con tremore essenziale (ET).
Le presentazioni si concentreranno sul programma Essential3, un'iniziativa innovativa di Fase 3 che valuta l'efficacia e la sicurezza di ulixacaltamide. Praxis sarà disponibile allo stand #1008 e presenterà una presentazione piattaforma il 28 settembre e una presentazione poster il 29 settembre. I materiali delle presentazioni saranno resi disponibili sul sito web dell'azienda dopo la conferenza.
Praxis Precision Medicines (NASDAQ: PRAX) ha anunciado su participación en el Congreso Internacional de la Society for Movement Disorders (MDS) 2024 en Filadelfia, Pennsylvania, del 27 de septiembre al 1 de octubre de 2024. La compañía presentará un póster y una charla en plataforma que mostrará su programa clínico de Fase 3 para ulixacaltamide, una terapia potencial para adultos con temblor esencial (ET).
Las presentaciones se centrarán en el programa Essential3, una iniciativa innovadora de múltiples estudios en Fase 3 que evalúa la eficacia y seguridad de ulixacaltamide. Praxis estará disponible en el puesto #1008 y realizará una presentación en plataforma el 28 de septiembre y una presentación de póster el 29 de septiembre. Los materiales de las presentaciones estarán disponibles en el sitio web de la empresa después de la conferencia.
프랙시스 프리시전 메디슨스 (NASDAQ: PRAX)는 2024년 9월 27일부터 10월 1일까지 필라델피아, 펜실베이니아에서 열리는 운동장애학회(MDS) 국제 congress에 참여할 예정이라고 발표했습니다. 이 회사는 성인 필수 떨림(ET)을 위한 잠재적 치료제인 울릭사칼타미드에 대한 3상 임상 프로그램을 선보이는 포스터 및 플랫폼 발표를 하게 됩니다.
발표는 울릭사칼타미드의 효능과 안전성을 평가하는 혁신적인 다중 연구 3상 프로그램인 Essential3 프로그램에 중점을 둘 것입니다. 프랙시스는 부스 #1008에서 대기하며 9월 28일에 플랫폼 발표와 9월 29일에 포스터 발표를 진행할 것입니다. 발표 자료는 회의 이후 회사 웹사이트에 게시될 예정입니다.
Praxis Precision Medicines (NASDAQ: PRAX) a annoncé sa participation au Congrès International de la Movement Disorders Society (MDS) 2024 à Philadelphie, en Pennsylvanie, du 27 septembre au 1er octobre 2024. L'entreprise présentera un poster et une présentation sur plateforme mettant en avant son programme clinique de Phase 3 pour ulixacaltamide, une thérapie potentielle pour les adultes atteints de tremblement essentiel (ET).
Les présentations se concentreront sur le programme Essential3, une initiative innovante de Phase 3 qui évalue l'efficacité et la sécurité de l'ulixacaltamide. Praxis sera disponible au stand #1008 et donnera une présentation sur plateforme le 28 septembre ainsi qu'une présentation de poster le 29 septembre. Les matériaux de présentation seront accessibles sur le site web de l'entreprise après la conférence.
Praxis Precision Medicines (NASDAQ: PRAX) hat seine Teilnahme am Internationalen Kongress der Movement Disorders Society (MDS) 2024 in Philadelphia, Pennsylvania, vom 27. September bis 1. Oktober 2024 angekündigt. Das Unternehmen wird ein Poster und einen Plattformvortrag präsentieren, der sein Phase 3 klinisches Programm für Ulixacaltamid, eine potenzielle Therapie für Erwachsene mit essentieller Tremor (ET), vorstellt.
Die Präsentationen werden sich auf das Essential3-Programm konzentrieren, eine innovative multi-studien-Phase-3-Initiative, die die Wirksamkeit und Sicherheit von Ulixacaltamid bewertet. Praxis wird am Stand #1008 vertreten sein und am 28. September einen Plattformvortrag sowie am 29. September eine Posterpräsentation halten. Die Präsentationsmaterialien werden nach der Konferenz auf der Website des Unternehmens verfügbar sein.
- Praxis is presenting Phase 3 clinical program data for ulixacaltamide in essential tremor
- The company has a presence at a major international conference (MDS 2024)
- Praxis is advancing to late-stage clinical trials for its essential tremor therapy
- None.
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the presentation of a poster and platform talk showcasing its Phase 3 clinical program evaluating ulixacaltamide for adults with essential tremor (ET) at the Movement Disorders Society (MDS) 2024 International Congress taking place in Philadelphia, Pennsylvania, September 27 – October 1, 2024.
Praxis at MDS 2024 | Pennsylvania Convention Center
Meet us at booth #1008 or head to one of our presentations listed below where we will share progress on our journey to develop a new ET therapy
Essential3: An Innovative Multi-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide
Platform Presentation
- Saturday, September 28
1:30 – 2:30 PM ET | Group 1: Clinical Trials | Meeting Room 204C
Poster Presentation
- Sunday, September 29
1:00 – 3:00 PM ET | Poster #641 | Exhibit Hall A
Materials will be made available on the Resources page of the Praxis website following presentation at MDS 2024: https://praxismedicines.com/resources/.
About Ulixacaltamide
Ulixacaltamide is a differentiated and highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical (CTC) circuit correlated with tremor activity. Ulixacaltamide, the most advanced program within Praxis’ Cerebrum™ small molecule platform, is currently in development for the treatment of essential tremor. www.praxisessentialtremor.com.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn, Instagram and Twitter/X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Praxis’ future expectations, plans and prospects, including, without limitation, statements regarding the anticipated timing of Praxis’ clinical trials, the development of Praxis’ product candidates and the potential therapeutic effects of Praxis’ product candidates, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “endeavor,” “estimate,” “expect,” “anticipate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would” and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995.
The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical trials; the expected timing of clinical trials, data readouts and the results thereof, and submissions for regulatory approval or review by governmental authorities; regulatory approvals to conduct trials; and other risks concerning Praxis’ programs and operations as described in its Annual Report on Form 10-K for the year ended December 31, 2023 and other filings made with the Securities and Exchange Commission. Although Praxis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on information and factors currently known by Praxis. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
FAQ
What is Praxis Precision Medicines presenting at the MDS 2024 International Congress?
When and where is the MDS 2024 International Congress taking place?
What is the name of Praxis Precision Medicines' Phase 3 program for essential tremor?